BiotechTube

KPS-0373 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinocerebellar Degeneration

Conditions

Spinocerebellar Degeneration

Trial Timeline

Jul 1, 2025 → Mar 31, 2027

NCT ID
NCT07040137

About KPS-0373 + Placebo

KPS-0373 + Placebo is a phase 3 stage product being developed by Kissei Pharmaceutical for Spinocerebellar Degeneration. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07040137. Target conditions include Spinocerebellar Degeneration.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT01004016Phase 2Completed
NCT07040137Phase 3Recruiting
NCT02889302Phase 3Completed

Competing Products

15 competing products in Spinocerebellar Degeneration

See all competitors
ProductCompanyStageHype Score
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
76
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
KPS-0373 + PlaceboKissei PharmaceuticalPhase 2
51
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
76
KPS-0373Kissei PharmaceuticalPhase 2
51
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
varenicline + placeboPfizerPhase 2
51
BIIB132 + BIIB132-Matching PlaceboBiogenPhase 1
30
IVIGBaxterPhase 2
49
Intravenous Immune Globulin (IVIG)BaxterPhase 1
30
ARO-ATXN2 Injection + PlaceboArrowhead PharmaceuticalsPhase 1
30
Troriluzole + Placebo + TroriluzoleBiohavenPhase 2/3
60
BHV-4157BiohavenPre-clinical
18
troriluzole + PlaceboBiohavenPhase 3
72

Other Products from Kissei Pharmaceutical

KAD-1229 + Placebo + InsulinApproved
84
Avacopan, prednisolone and rituximab + Prednisolone and rituximabApproved
84
KLH-2109 + LeuprorelinPhase 3
76
KAD-1229Phase 3
76
KUC-7483 + Placebo + TolterodinePhase 3
76